Winvest Group’s IQI Media strikes strategic deal with BioCalth to power direct-to-consumer health supplement sales

Winvest Group Limited (OTCQB: WNLV), an investment holding company with portfolios spanning media, entertainment, and technology, has announced that its subsidiary IQI Media Inc. has entered a strategic partnership with BioCalth International Inc. The agreement is designed to expand BioCalth’s direct-to-consumer sales model, with the two companies aligning on profit-sharing incentives that could transform BioCalth’s revenue mix and visibility in the competitive health supplements industry.

How does the IQI Media partnership aim to transform BioCalth’s direct-to-consumer sales momentum?

The newly inked agreement provides IQI Media with both a fixed monthly retainer and a profit participation model that scales as BioCalth’s online conversions grow. Specifically, IQI Media becomes eligible for a percentage of profit margin once net revenue from digital conversions surpasses the $30,000 mark, potentially scaling up beyond $1 million in topline e-commerce sales.

This tiered structure signals a performance-driven alignment between Winvest and BioCalth, incentivizing IQI Media to focus not just on brand visibility but on measurable outcomes tied to customer acquisition and digital transaction growth. BioCalth, historically a business-to-business player exporting through global retailers, is now positioning itself to capture recurring direct consumer spending in an era where e-commerce penetration of nutraceuticals has accelerated post-pandemic.

By leveraging IQI Media’s storytelling capabilities, the companies intend to drive traffic for BioCalth’s flagship product, calcium L-threonate, an ingredient patented and clinically validated for superior absorption. IQI Media founder Khiow Hui Lim emphasized that this marks BioCalth’s first dedicated e-commerce store, designed to appeal to younger, digitally savvy consumers who rely on direct brands for wellness needs.

Why is calcium l-threonate positioned as a potential disruptor in the supplements industry?

Calcium supplements are a highly commoditized market segment, but BioCalth has differentiated itself by investing in intellectual property protection and university-backed research. With three patents secured, BioCalth’s calcium L-threonate formula claims a 95% absorption rate, verified by laboratory testing at UCLA. This sets it apart from conventional calcium carbonate or calcium citrate products, which are often criticized for limited bioavailability.

BioCalth’s founder Jackson Wen highlighted that the formula’s high absorption is intended to support bone density and long-term skeletal health, key concerns for aging populations and wellness-focused consumers alike. By taking a science-first approach in marketing, the company is aligning its narrative with evidence-based wellness trends, a move increasingly necessary in an industry where regulatory scrutiny and consumer skepticism remain high.

IQI Media’s role in crafting top-of-funnel marketing campaigns will be to translate BioCalth’s scientific advantage into digestible narratives that build trust on social platforms, where health-conscious communities often drive purchase behavior. This signals an evolution from traditional supplement advertising toward data-driven storytelling aimed at capturing consumer loyalty directly at the awareness stage.

How does the manufacturing expansion at BioCalth’s California facility reinforce its growth ambitions?

Beyond marketing, BioCalth is investing in vertical integration to future-proof its supply chain. The company has expanded its state-of-the-art manufacturing facility in California, which is both FDA-registered and GMP-certified, ensuring compliance with strict quality standards. The site now features automation intelligence systems that streamline quality control and scalability.

Sophia Li, BioCalth’s Vice President of Marketing, explained that integrating sales, data analytics, and backend management is part of the company’s holistic growth plan. By providing contract manufacturing services for pharmaceutical and nutritional supplement companies, BioCalth is diversifying revenue streams while solidifying its credibility as a benchmark GMP-compliant manufacturer.

This dual strategy—direct-to-consumer e-commerce coupled with manufacturing services for third parties—positions BioCalth as both a brand owner and a behind-the-scenes enabler in the biotechnology and wellness industries. It reflects a broader sectoral trend where nutraceutical firms are blurring the lines between brand, contract manufacturer, and science-driven biotech.

What does this partnership mean for Winvest Group’s diversification strategy in media and technology?

For Winvest Group, the partnership demonstrates how its media subsidiaries can extend beyond traditional entertainment content into commerce enablement. IQI Media’s content creation and digital campaign expertise, originally cultivated for film and storytelling ventures, is now being deployed to drive measurable outcomes in retail and wellness.

This pivot aligns with the broader convergence of media and e-commerce, where consumer engagement increasingly relies on authentic narratives amplified through digital channels. By positioning IQI Media at the intersection of content and commerce, Winvest is signaling to investors that it sees growth potential in leveraging creative assets to capture transaction-driven revenues across industries.

Such diversification helps Winvest build resilience. Entertainment portfolios are often cyclical, but partnerships with essential consumer health brands like BioCalth create recurring revenue possibilities linked to wellness consumption, which remains resilient even during economic downturns.

How are investors and markets likely to interpret Winvest Group’s OTCQB performance after this announcement?

Winvest Group Limited trades on the OTCQB under the ticker WNLV, and while still a microcap stock, investor sentiment around such deals tends to be cautiously optimistic. Market watchers often see cross-sector partnerships as catalysts for revenue diversification, particularly when linked to consumer-facing industries like health and supplements.

In recent months, Winvest’s stock has reflected the volatility typical of smaller-cap companies on the OTCQB, with thin liquidity amplifying both gains and losses. Institutional flows remain limited, though news-driven catalysts like this partnership could attract speculative retail interest. The profit-sharing structure with BioCalth introduces a pathway to incremental revenues that analysts may model as high-margin digital growth, though execution risks around customer acquisition costs and conversion efficiency will remain central.

For investors, the question will be whether Winvest can scale such cross-industry ventures into consistent cash flows, making WNLV more attractive for buy-and-hold strategies rather than short-term speculative trading. Early sentiment suggests a neutral-to-positive tilt, with traders awaiting quarterly updates to quantify the impact of this partnership.

How does this move reflect broader industry trends in nutraceuticals, digital marketing, and biotech manufacturing?

This partnership lands at the intersection of three fast-moving industry narratives. First, nutraceuticals continue to expand globally, with consumer interest in preventive health, longevity, and wellness driving sustained demand. Second, the shift to direct-to-consumer sales models reflects how supplement companies are bypassing traditional retail bottlenecks in favor of personalized, recurring digital relationships. Third, biotech manufacturing infrastructure, particularly FDA-registered and GMP-certified facilities, is increasingly valuable as regulatory oversight tightens.

BioCalth’s hybrid approach—scientifically backed products, direct-to-consumer engagement, and manufacturing-as-a-service—mirrors how the wellness industry is professionalizing and converging with biotech standards. IQI Media’s participation underscores how media firms are also adapting, monetizing not only through creative output but by embedding themselves in digital sales ecosystems.

Taken together, this deal illustrates how cross-sector collaboration is becoming a defining feature of modern business, particularly in industries where consumer trust and brand credibility are tied to both science and storytelling.

What signals should stakeholders watch as the partnership progresses over the coming quarters?

Looking ahead, stakeholders will monitor several metrics: BioCalth’s direct-to-consumer revenue ramp, the profitability of its manufacturing services, and Winvest’s ability to report meaningful incremental revenue from its media subsidiary. Investors will also look for signals around cost efficiency, including how customer acquisition costs balance against high-margin product sales.

For BioCalth, successful traction would not only establish calcium L-threonate as a category leader but also create a template for how legacy supplement brands can reinvent themselves through digital-first commerce. For Winvest, proof of concept could lead to more such partnerships, potentially with companies in adjacent industries like personal care, functional foods, or wellness technology.

The underlying takeaway is that both companies are positioning themselves in growth lanes tied to macro trends: the consumerization of healthcare, the digitalization of commerce, and the globalization of GMP-standard manufacturing. If execution aligns with strategy, this partnership could mark a meaningful turning point for both BioCalth’s expansion ambitions and Winvest’s investor narrative.